Madrigal Pharmaceuticals, Inc. MDGL Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s operating lease liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported operating lease liabilities of $5.28M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s operating lease liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s operating lease liabilities increased by 604.5% year-over-year, from $750K to $5.28M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s operating lease liabilities has grown at a 70.4% compound annual growth rate (CAGR), from $468K to $6.73M.
- What does operating lease liabilities mean?
- Lease payments due after more than one year.
- How do you interpret operating lease liabilities?
- Stable or growing non-current lease liabilities suggest a long-term commitment to physical operational capacity.
- How does operating lease liabilities compare across companies?
- Comparable across companies with similar physical footprints and facility requirements.